GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer
GDC-0941 and CXCL8 (3-72) K11R/G31P combination therapy confers enhanced efficacy against breast cancer
复制标题
GDC-0941 和 CXCL8 (3-72) K11R/G31P 联合疗法可增强抗乳腺癌功效
DOI：
10.2217/fon-2020-0035
复制
发表时间：
2020-05-01
期刊：
影响因子：
3.3
通讯作者：
Luo, Fuwen
中科院分区：
文献类型：
--
作者：
Li, Xiaodong;Zhang, Yuanyue;Luo, Fuwen
目的：探讨PI3K抑制剂GDC-0941与CXCR1/2类似物G31P在乳腺癌中的联合作用。材料与方法：采用乳腺癌细胞系和异种移植瘤模型检测联合治疗的疗效。结果：GDC-0941+G31P处理显著抑制了本研究中使用的所有乳腺癌细胞系（BT474、HCC1954和4T1）的增殖。尽管单一治疗引起了有意义的s期细胞周期阻滞，但联合治疗的抑制效果更强。同样，GDC-0941+G31P处理可增强细胞凋亡。此外，与单一治疗相比，联合治疗显著降低了乳腺癌细胞系的迁移能力。结论：PI3K抑制剂与CXCR1/2类似物（G31P）联合治疗可能是一种有效的乳腺癌治疗选择。
Aim: Herein is presented the combined effect of PI3K inhibitor (GDC-0941) and CXCR1/2 analogue (G31P) in breast cancer. Materials & methods: Breast cancer cell lines and xenograft model were employed to test the efficacy of the combination therapy. Results: GDC-0941+G31P treatment substantially inhibited multiplication of all the breast cancer cell lines used in this study (BT474, HCC1954 and 4T1). Even though single therapies caused a meaningful S-phase cell cycle arrest, the inhibition effect was more potent with the combined treatment. Similarly, enhanced apoptosis accompanied GDC-0941+G31P treatment. Furthermore, the migration ability of the breast cancer cell lines were significantly curtailed by the combination therapy compared with the single treatments. Conclusion: The findings suggest that combination treatment involving PI3K inhibitor and CXCR1/2 analogue (G31P) could be a potent therapeutic option for breast cancer treatment.